Bausch Health Companies Inc. Stock
Bausch Health Companies Inc. gained 1.370% today.
Our community is currently high on Bausch Health Companies Inc. with 3 Buy predictions and 0 Sell predictions.
With a target price of 16 € there is a hugely positive potential of 96.44% for Bausch Health Companies Inc. compared to the current price of 8.15 €.
Our community identified positive and negative aspects for Bausch Health Companies Inc. stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Bausch Health Companies Inc. stock. On the other hand our users think that "Revenue growth" could be a problem in the future.
Pros and Cons of Bausch Health Companies Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Bausch Health Companies Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Bausch Health Companies Inc. | 1.370% | -0.196% | -17.141% | 21.876% | 12.159% | -69.654% | -61.544% |
Opko Health Inc. | 1.930% | 1.068% | 5.618% | -11.763% | -17.670% | -65.876% | -45.280% |
Catalent Inc. | 0.330% | 0.384% | -0.076% | 14.857% | 26.845% | -44.107% | 52.184% |
Repligen Corp. | -1.120% | 4.746% | -9.224% | 12.119% | -7.816% | -14.782% | - |
Comments
Bausch Health Companies Inc. (NYSE: BHC) had its price target lowered by analysts at Jefferies Financial Group Inc. from $16.00 to $14.00. They now have a "buy" rating on the stock.
Show more
Ratings data for BHC provided by MarketBeat
Bausch Health Companies Inc. (NYSE: BHC) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for BHC provided by MarketBeat
News
CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
Approval Represents an Important Breakthrough in One of the Largest Medical Aesthetics Markets
(*CORRECTION to the release that was posted earlier on January 18, 2024: The TR-4 Return Pad i